BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences (AURA), Inc. (NASDAQ: AURA), today announced positive data from a completed Phase 1 window of opportunity trial of bel-sar (AU-011) in ...
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback